Cancer risk in chronic rhinosinusitis: a propensity score matched case-control cohort study.
Chronic rhinosinusitis
cancer
case-control
risk
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
08
2019
accepted:
04
11
2019
entrez:
10
12
2019
pubmed:
10
12
2019
medline:
10
12
2019
Statut:
epublish
Résumé
Chronic rhinosinusitis (CRS) have infection, innate immune disorder and chronic inflammation problems which are considered as potential mechanism of tumorigenesis. To estimate cancer risk in CRS using propensity scores matching (PSM) case-control cohort study. A nationwide retrospective case-control cohort study is conducted on claim data from National Health Insurance Research Database in Taiwan. From January 2000 to December 2005, case group included 32677 CRS patients (including 544 with surgery in case 1 group and 32133 without surgery in case 2 group), and control group included 98031 subjects without CRS which were matching by PSM method on all baseline characteristics. All subjects were followed up from January 2006 till December 2013, the risk of cancers were calculated during the period. Conditional logistic regression Analysis of Cancer Risk is used to calculate the odds ratio (OR) and 95% confidence interval (CI) for case, case 1 and case 2 compared with control group. The difference in cancer risk among case, case 1 and case 2 drew the conclusions of this paper. The risk of cancers in head and neck (adjusted OR: 1.53, 95% CI: 1.33-1.75), colon (adjusted OR: 1.23, 95% CI: 1.09-1.39), liver (adjusted OR: 1.24, 95% CI: 1.09-1.41), lung (adjusted OR: 1.14, 95% CI: 1-1.3), skin (adjusted OR: 1.37, 95% CI: 1.05-1.79), breast (adjusted OR: 1.17, 95% CI: 1.01-1.36), prostate (adjusted OR: 1.85, 95% CI: 1.54-2.22) and bladder (adjusted OR: 1.48, 95% CI: 1.17-1.48) were statistical significantly higher in CRS patients than non-CRS group. Compared with CRS patients without surgery, risk of cancers in head and neck, colon, liver, lung, skin, breast, and prostate were higher in CRS patients receiving surgery. Cancer risk in CRS patients is significant high than non-CRS patients, especially in head and neck, breast, lung, bladder, colorectal, liver, prostate, and skin cancers. Surgical interventions in CRS patients could not decrease cancer risk in CRS patients.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic rhinosinusitis (CRS) have infection, innate immune disorder and chronic inflammation problems which are considered as potential mechanism of tumorigenesis. To estimate cancer risk in CRS using propensity scores matching (PSM) case-control cohort study.
METHODS
METHODS
A nationwide retrospective case-control cohort study is conducted on claim data from National Health Insurance Research Database in Taiwan. From January 2000 to December 2005, case group included 32677 CRS patients (including 544 with surgery in case 1 group and 32133 without surgery in case 2 group), and control group included 98031 subjects without CRS which were matching by PSM method on all baseline characteristics. All subjects were followed up from January 2006 till December 2013, the risk of cancers were calculated during the period. Conditional logistic regression Analysis of Cancer Risk is used to calculate the odds ratio (OR) and 95% confidence interval (CI) for case, case 1 and case 2 compared with control group. The difference in cancer risk among case, case 1 and case 2 drew the conclusions of this paper.
RESULTS
RESULTS
The risk of cancers in head and neck (adjusted OR: 1.53, 95% CI: 1.33-1.75), colon (adjusted OR: 1.23, 95% CI: 1.09-1.39), liver (adjusted OR: 1.24, 95% CI: 1.09-1.41), lung (adjusted OR: 1.14, 95% CI: 1-1.3), skin (adjusted OR: 1.37, 95% CI: 1.05-1.79), breast (adjusted OR: 1.17, 95% CI: 1.01-1.36), prostate (adjusted OR: 1.85, 95% CI: 1.54-2.22) and bladder (adjusted OR: 1.48, 95% CI: 1.17-1.48) were statistical significantly higher in CRS patients than non-CRS group. Compared with CRS patients without surgery, risk of cancers in head and neck, colon, liver, lung, skin, breast, and prostate were higher in CRS patients receiving surgery.
CONCLUSION
CONCLUSIONS
Cancer risk in CRS patients is significant high than non-CRS patients, especially in head and neck, breast, lung, bladder, colorectal, liver, prostate, and skin cancers. Surgical interventions in CRS patients could not decrease cancer risk in CRS patients.
Types de publication
Journal Article
Langues
eng
Pagination
7146-7156Informations de copyright
AJTR Copyright © 2019.
Déclaration de conflit d'intérêts
None.
Références
Compr Physiol. 2013 Jul;3(3):1191-212
pubmed: 23897684
Curr Opin Pharmacol. 2009 Aug;9(4):389-95
pubmed: 19570715
Cochrane Database Syst Rev. 2016 Apr 26;4:CD011994
pubmed: 27113482
BMC Gastroenterol. 2005 Sep 06;5:28
pubmed: 16144553
Can J Gastroenterol. 2007 Jul;21(7):443-6
pubmed: 17637947
Front Microbiol. 2018 Apr 20;9:774
pubmed: 29731748
Br J Cancer. 2014 May 27;110(11):2796-803
pubmed: 24691420
Am J Rhinol Allergy. 2013 Sep-Oct;27(5):367-71
pubmed: 23601202
Int J Hepatol. 2018 Dec 2;2018:1941728
pubmed: 30631602
Gastroenterology. 2001 Jan;120(1):323-4
pubmed: 11246512
Am J Rhinol Allergy. 2014 Jul-Aug;28(4):168-72
pubmed: 25197911
J Clin Invest. 2007 May;117(5):1175-83
pubmed: 17476347
Gut. 2005 Mar;54(3):396-401
pubmed: 15710989
Int J Mol Sci. 2017 Jun 24;18(7):null
pubmed: 28672809
Shock. 2005 Sep;24(3):206-9
pubmed: 16135957
Dig Dis Sci. 2016 Jan;61(1):255-64
pubmed: 26289256
Cochrane Database Syst Rev. 2016 Apr 26;4:CD011993
pubmed: 27115215
Clin Respir J. 2016 Jul;10(4):435-9
pubmed: 25354161
Int J Cancer. 2008 Sep 15;123(6):1398-402
pubmed: 18548585
World J Gastroenterol. 2008 Jul 7;14(25):3937-47
pubmed: 18609676
Laryngoscope. 2004 May;114(5):923-30
pubmed: 15126758
Cochrane Database Syst Rev. 2016 Apr 26;4:CD011995
pubmed: 27115216
Am J Gastroenterol. 2013 Feb;108(2):208-15
pubmed: 23208272
Cochrane Database Syst Rev. 2016 Apr 26;4:CD011996
pubmed: 27115217
Lancet Infect Dis. 2008 Apr;8(4):254-60
pubmed: 18353266
JAMA Otolaryngol Head Neck Surg. 2017 Jan 1;143(1):25-31
pubmed: 27606895
Eye (Lond). 2014 Feb;28(2):225-30
pubmed: 24263380
Cancers (Basel). 2019 Aug 14;11(8):null
pubmed: 31416208
World J Gastroenterol. 2004 Feb 15;10(4):598-601
pubmed: 14966925
Genes Dis. 2016 Jun;3(2):130-143
pubmed: 28078319
Curr Infect Dis Rep. 2011 Apr;13(2):159-68
pubmed: 21365379
Cochrane Database Syst Rev. 2016 Apr 26;4:CD011992
pubmed: 27115214
BMC Gastroenterol. 2005 Mar 03;5:6
pubmed: 15745456
Clin Transl Allergy. 2014 Jun 04;4:20
pubmed: 24976949
Adv Exp Med Biol. 2014;816:107-27
pubmed: 24818721
Laryngoscope. 2012 Jan;122(1):225-9
pubmed: 22183638
Acta Otolaryngol. 2008 Jul;128(7):778-84
pubmed: 18568521
Gut. 2010 Jan;59(1):88-97
pubmed: 19850960
Semin Immunopathol. 2015 Jan;37(1):65-72
pubmed: 25404117
Sci Rep. 2016 Apr 07;6:23979
pubmed: 27052782
Breast Cancer Res. 2007;9(4):212
pubmed: 17705880
Laryngoscope Investig Otolaryngol. 2016 Jun;1(3):49-56
pubmed: 28459101
Am J Rhinol Allergy. 2013 Nov-Dec;27(6):482-9
pubmed: 24274224
J Natl Cancer Inst. 2004 May 5;96(9):709-11
pubmed: 15126608
Br J Cancer. 2009 Jan 13;100(1):200-5
pubmed: 19034275
J Laryngol Otol. 2018 Jul;132(7):567
pubmed: 30058521
J Allergy Clin Immunol. 2001 Sep;108(3):466-7
pubmed: 11544470
World J Gastroenterol. 2006 Apr 21;12(15):2335-40
pubmed: 16688821
Cytokine Growth Factor Rev. 2005 Feb;16(1):35-53
pubmed: 15733831
Am J Rhinol. 2003 Mar-Apr;17(2):87-90
pubmed: 12751702
Cochrane Database Syst Rev. 2016 Apr 26;4:CD011991
pubmed: 27113367
J Allergy Clin Immunol. 2011 Oct;128(4):693-707; quiz 708-9
pubmed: 21890184
J Allergy Clin Immunol. 2015 Jul;136(1):38-48
pubmed: 25457152
J Allergy Clin Immunol. 2006 Nov;118(5 Suppl):S17-61
pubmed: 17084217
Otolaryngol Head Neck Surg. 2003 Sep;129(3 Suppl):S1-32
pubmed: 12958561
Microorganisms. 2019 May 05;7(5):null
pubmed: 31060311